当然，风险亦不容忽视。Infigratinib是泛FGFR1-4抑制剂，对FGFR1等的抑制可能引起高磷血症等副作用。3期试验中约有4%患者出现轻度、短暂的高磷血症。在儿科长期用药的背景下，其安全性仍需更严格的监测，监管的要求也会更严格。
for (int i = 1; i < n; i++) {
，这一点在搜狗输入法下载中也有详细论述
Ian YoungsCulture reporter, Mama Roux's, Birmingham
He only learned it had been aired on TV when he saw his phone around 03:00 GMT, including messages from the US as the news reached it.